rethinkTHC Search
Menu
Study breakdown

Too Little Evidence to Recommend Cannabis for Depression, Anxiety, or PTSD

Systematic ReviewModerate evidence
The takeaway

A systematic review found only 8 very small randomized controlled trials testing cannabinoids for mood disorders, anxiety, or PTSD, and concluded there is insufficient evidence to recommend medical cannabis for any of these conditions.

Psychiatrists, medical cannabis prescribers, mental health patients considering cannabis

Only 8 randomized controlled trials exist for cannabinoids in mood disorders, anxiety, or PTSD

What the researchers found

Of 8 identified RCTs, CBD pretreatment showed promise for social anxiety in laboratory settings, but THC showed no benefit for depression and actually worsened anxiety and psychotic symptoms in over 50% of hospitalized depression patients. One small crossover trial found THC reduced PTSD nightmares.

Why it matters

Despite widespread use of cannabis for mental health symptoms, this review reveals that the controlled evidence base is remarkably thin, with only 8 small trials across three major diagnostic categories.

The numbers in context

8 RCTs identified; CBD: 3 studies showed anxiety reduction in social anxiety; THC up to 3 mg/day reduced anxiety in 1 trial but symptoms were already low; THC worsened anxiety/psychotic symptoms in >50% of depression patients; 1 crossover trial of 10 PTSD patients found THC reduced nightmares.

How the study worked

Systematic review searching 8 online databases for randomized controlled trials of defined CBD or THC doses in populations with affective disorders, anxiety disorders, or PTSD.

What this study cannot tell us

Only 8 very small trials identified; heterogeneous designs, doses, and populations; insufficient evidence to draw definitive conclusions about either efficacy or harm.

How to read the evidence

Systematic review revealing a near-total absence of controlled evidence, limiting conclusions despite moderate review quality.

When this study was published

Review published in 2021.

The bigger picture

The mismatch between the large number of people using cannabis for mental health and the tiny number of controlled trials creates a significant evidence gap that leaves both patients and clinicians without reliable guidance.

Questions still open

  • Why are there so few controlled trials of cannabinoids for common psychiatric conditions? Would larger, well-designed RCTs reveal benefits that small studies miss?

Common questions

Should I use cannabis for anxiety or depression?
This systematic review found insufficient controlled evidence to recommend cannabinoids for anxiety, depression, or PTSD. While CBD showed some promise for social anxiety in lab settings, THC actually worsened symptoms in depression patients in the available studies.
Does cannabis help with PTSD?
Only one very small crossover trial (10 patients) found that THC reduced self-reported nightmares when added to standard PTSD treatment. This is insufficient evidence to draw conclusions.

Read the original research

Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.

Psychiatric services (Washington, D.C.), 72(4), 429-436

Citation

Stanciu, Corneliu N; Brunette, Mary F; Teja, Nikhil; Budney, Alan J. (2021). Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.. Psychiatric services (Washington, D.C.), 72(4), 429-436. https://doi.org/10.1176/appi.ps.202000189

Explore the wider topic